A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation

Bone Marrow Transplantation

Volumn 42, Issue 8, 2008, Pages 535-539

  Liu, K Y ^a   Chen, Y H ^a   Liu, D H ^a   Xu, L P ^a   Huang, X J ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT INTERLEUKIN 2; SEMUSTINE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HLA SYSTEM; HUMAN; HYPERPYREXIA; INJECTION SITE PAIN; INJECTION SITE SWELLING; KIDNEY DYSFUNCTION; LEUKEMIA RELAPSE; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; PILOT STUDY; PRIORITY JOURNAL; RASH; SKIN REDNESS;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; PILOT PROJECTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RISK FACTORS; YOUNG ADULT;

EID: 55549111852     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.208     Document Type: Article

References (25)

1. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
2. Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control 2004; 11: 97-104.
3. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
4. Weiden PL, Flournoy N, Thomas ED" Fefer A, Buckner CD et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068-1073.
5. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L. The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD? Bone Marrow Transplant 1990; 6: 155-161.
6. Schleuning M. Adoptive allogeneic immunotherapy-history and future perspectives. Transfus Sci 2000; 23: 133-150.
7. Sykes M, Harty MW, Szot GL. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 1994; 83: 2560-2569.
8. Weiss L, Reich S, Slavin S. Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 6: 229-233.
9. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB et al Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898-905.
10. Robinson N, Sanders JE, Benyunes MC, Beach K, Lindgren C, Thompson JA et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 1996; 87: 1249-1254.
11. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human IL-2 to treat leukemia relapse after allogeneic BMT. Blood 1996; 87: 2195-2204.
12. Nadala E, Fowlerb A, Kanfera E, Apperley J, Goldman J, Dazzi F. Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Exp Hematol 2004; 32: 218-223.
13. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065-3073.
14. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291-297.
15. Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983; 302: 305-310.
16. Smith KA. Interleukin-2: Inception, impact, and implications. Science 1988; 240: 1169-1176.
17. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4: 665-674.
18. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol 2004; 172: 3983-3988.
19. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D et al. IL-2 regulates FOXP3 expression in human CD4 + CD25 + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571-1579.
20. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL et al Graft-versus-host-disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320: 828-834.
21. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW et al. T-cell depletion of HLA identical transplants in leukemia. Blood 1991; 78: 2120-2130.
22. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995; 85: 3302-3312.
23. Billiau AD, Fevery S, Rutgeerts O, Landuyt W, Waer M. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. Blood 2002; 100: 1894-1902.
24. Huang XJ, Liu DH, Xu LP, Chen H, Han W, Liu KY et al. Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral progenitor cells after allogeneic hematopoietic stem cell transplantation in patients with high-risk leukemia. Leukemia 2006; 20: 365-368.
25. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/ haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92: 414-417.